FY2025 · ended Dec 31, 2025 · Revenue $344.23M, +3.7% YoY · Filed Feb 26, 2026
Castle Biosciences, Inc. (CSTL) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $344.2 million and a net loss of $24.2 million. Free cash flow was $28.3 million. As of Sep 30, 2026 it held $277.7 million in cash and investments and $36.6 million in total debt.
Revenue (TTM)
$377.13M
+9.8% vs year-ago TTM
Net income (TTM)
$-23.01M
-88.1% vs year-ago TTM
Operating cash flow (TTM)
$39.74M
-35.7% vs year-ago TTM
Free cash flow (TTM)
$3.96M
-84.4% vs year-ago TTM
EPS (TTM)
$-0.77
-84.1% vs year-ago TTM
Dividend per share
$0.00
Shares outstanding
29.73M
+4.3% vs prior year
Net cash
$241.09M
as of Sep 30, 2026
Operating margin
-7.4%
FY 2026
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- CSTL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Friendswood, TX
- SEC filer status
- Accelerated filer
- SEC CIK
- 1447362
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $344.2M | $332.1M | $219.8M | $137.0M | $94.1M |
| Operating income | -$42.8M | $8.7M | -$68.0M | -$72.9M | -$40.1M |
| Net income | -$24.2M | $18.2M | -$57.5M | -$67.1M | -$31.3M |
| Diluted EPS | -$0.83 | $0.62 | -$2.14 | -$2.58 | -$1.24 |
| Operating cash flow | $64.3M | $64.9M | -$5.6M | -$41.7M | -$19.0M |
| Free cash flow | $28.3M | $36.5M | -$19.2M | -$47.3M | -$22.5M |
| Total assets | $578.6M | $531.2M | $453.3M | $447.3M | $462.6M |
| Total liabilities | $107.7M | $75.4M | $62.1M | $48.2M | $50.8M |
| Stockholders' equity | $470.9M | $455.8M | $391.3M | $399.1M | $411.7M |
| Cash and investments | $299.5M | $293.1M | $243.1M | $258.6M | $329.6M |
| Total debt | $37.0M | $26.4M | $15.4M | $13.5M | $8.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 29, 2026 | May 28, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
All 890 Castle Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.